Anja Sandström
Professor at Institutionen för läkemedelskemi; Läkemedelsdesign och läkemedelsutveckling
- Telephone:
- +46 70 167 97 76, +46 18 471 50 26
- Fax:
- +46 18 471 44 74
- E-mail:
- anja.sandstrom@ilk.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postal address:
- Box 574
751 23 UPPSALA
More information is available to staff who log in.
Short presentation
This text is not available in English, therefore the Swedish version is shown.
I currently serve as the Deputy Dean of Education at the Faculty of Pharmacy. Additionally, I have been recognized as an excellent teacher and hold the position as professor in Medicinal Chemistry. My research interests primarily focus on peptides and peptidomimetics in drug discovery.
Biography
I earned a Master's degree in Pharmacy in 1997 and completed my PhD in medicinal chemistry in 2003, studying under Professor Anders Hallberg at Uppsala University. I started my career at the same university as a research scientist. I became an associate professor (docent) in 2009 and a university lecturer in 2011. In 2013, I spent time as a STINT fellow at Amherst College in Massachusetts, USA. Over the years, I've received several teaching awards from Uppsala University and the Pharmaceutical Student Union. In 2017, I was recognized as an excellent teacher, and in 2021, I was promoted to the position of Professor. I've also taken on various leadership roles, including Study Director and Deputy and Assistant Head of the Department of Medicinal chemistry. Currently, I serve as the Deputy Dean of Education at the Faculty of Pharmacy. My research primarily focuses on peptides and peptidomimetics in drug discovery, with a special interest in developing pharmaceutical compounds for infectious diseases.
Publications
Recent publications
- Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses (2022)
- Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors (2021)
- Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors (2021)
- The amino-terminal heptapeptide of the algesic substance P provides analgesic effect in relieving chronic neuropathic pain (2021)
- Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease (2020)
All publications
Articles
- Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses (2022)
- Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors (2021)
- Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors (2021)
- The amino-terminal heptapeptide of the algesic substance P provides analgesic effect in relieving chronic neuropathic pain (2021)
- Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease (2020)
- Macrocyclic Peptidomimetics as Inhibitors of Insulin-Regulated Aminopeptidase (IRAP) (2020)
- Solid Phase Synthesis of Sulfonimidamide Pseudopeptides and Library Generation (2020)
- Synthesis of Sulfonimidamide-Based Amino Acid Building Blocks with Orthogonal Protecting Groups (2019)
- Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold (2018)
- From the Anti-Nociceptive Substance P Metabolite Substance P (1-7) to Small Peptidomimetics (2018)
- An imidazole based H-Phe-Phe-NH2 peptidomimetic with anti-allodynic effect in spared nerve injury mice (2018)
- Palladium-Catalyzed Aminocarbonylation in Solid-Phase Peptide Synthesis (2017)
- Impact of N-methylation of the substance P 1-7 amide on anti-allodynic effect in mice after peripheral administration (2017)
- Importance of N-and C-terminal residues of substance P 1-7 for alleviating allodynia in mice after peripheral administration (2017)
- Discovery of pyrazinone based compounds that potently inhibit the drug resistant enzyme variant R155K of the hepatitis C virus NS3 protease (2016)
- Efficient and Selective Palladium-Catalysed C-3 Urea Couplings to 3,5-Dichloro-2(1H)-pyrazinones (2015)
- Palladium-Catalyzed Carbonylation of Aryl Iodides with Sulfinamides (2015)
- Preclinical Characterization of Acyl Sulfonimidamides (2015)
- Small constrained SP1-7 analogues bind to a unique site and promote anti-allodynic effects following systemic injection in mice (2015)
- Synthesis of Vinyl- and Aryl–Acyl Sulfonimidamides Through Pd-Catalyzed Carbonylation Using Mo(CO)6 as ex situ CO Source (2015)
- N-terminal truncations of substance P1-7 amide affect its action on spinal cord injury-induced mechanical allodynia in rats (2014)
- Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues (2014)
- Achiral Pyrazinone-Based Inhibitors of the Hepatitis C Virus NS3 Protease and Drug-Resistant Variants with Elongated Substituents Directed Toward the S2 Pocket (2014)
- Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles (2014)
- Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region (2014)
- Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor (2013)
- Constrained H-Phe-Phe-NH2 Analogues With High Affinity to the Substance P 1-7 Binding Site and With Improved Metabolic Stability and Cell Permeability (2013)
- Aminocarbonylation of 4-Iodo-1H-imidazoles with an Amino Acid Amide Nucleophile (2013)
- Synthesis of functionalized furopyrazines as restricted dipeptidomimetics (2012)
- P2-P1 ' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis (2011)
- The effect of substance P1-7 amide on nociceptive threshold in diabetic mice (2011)
- The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system (2011)
- Discovery of Dipeptides with High Affinity to the Specific Binding Site for Substance P1-7 (2010)
- Hepatitis C protease inhibitors based on 2(1H)-pyrazinones (2010)
- Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents (2010)
- Discovery of Achiral Inhibitors of the Hepatitis C Virus NS3 Protease based on 2(1H)-pyrazinones (2010)
- Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V (2010)
- Hepatitis C virus NS3 protease inhibitors (2009)
- A straightforward microwave method for rapid synthesis of N-1, C-6 functionalized 3,5-dichloro-2(1H)-pyrazinones (2009)
- The C-terminal amidated analogue of the Substance P (SP) fragment SP (1-7) attenuates the expression of naloxone- precipitated withdrawal in morphine dependent rats (2009)
- Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality (2008)
- β-Amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors (2008)
- Hepatitis C Virus NS3 Protease Inhibitors Comprising a Novel Aromatic P1 Moiety (2008)
- New developments in the discovery of agents to treat hepatitis C (2008)
- Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3 (2007)
- Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3 (2007)
- Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3 (2007)
- Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors (2007)
- Phenylglycine as a Novel P2 Scaffold in Hepatitis C Virus NS3 Protease Inhibitors (2007)
- Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3 (2006)
- Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors (2004)
- Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase) (2003)
- Vinyl sulfide cyclized analogues of angiotensin II with high affinity and full agonist activity at the AT(1) receptor (2002)
- Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase) (2002)
- Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain (2001)
- An Improved Procedure for N- to C-Directed (Inverse) Solid-Phase Peptide Synthesis (2000)
- Identification of unique and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries
- Design, synthesis, and in vitro biological evaluation of meta-sulfonamidobenzamide-based antibacterial LpxH inhibitors
- Novel peptidomimetic HCV NS3 protease inhibitors spanning the P2-P1´ region
Books
Chapters
Conferences
